Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | HRH1 | P35367 | 2/20 | 0.54 |
| ▸ | TACR2 | P21452 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | PDE6D | O43924 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13317058 | 0.88 | KDM4E (0.54) | KDM4EPOLBHRH1TACR2TACR1 | |
| Bromide SCHEMBL9695606 | 0.85 | POLB (0.62) | KDM4EPOLBHRH1TACR2TACR1 | |
| SCHEMBL9266568 | 0.83 | HRH1 (0.66) | HRH1TACR2TACR1L3MBTL1SMN1; SMN2 | |
| SCHEMBL6993510 | 0.83 | L3MBTL1 (0.48) | KDM4EPOLBL3MBTL1MEN1KMT2A | |
| Fumaric Acid SCHEMBL9697232 | 0.82 | POLB (0.58) | KDM4EPOLBHRH1TACR2TACR1 | |
| SCHEMBL3555222 | 0.81 | KDM4E (0.47) | KDM4EPOLBL3MBTL1MEN1KMT2A | |
| SCHEMBL9695580 | 0.80 | POLB (0.60) | KDM4EPOLBHRH1TACR2TACR1 | |
| SCHEMBL7899281 | 0.79 | HRH1 (0.54) | HRH1TACR2TACR1PDE6DSMN1; SMN2 | |
| SCHEMBL9260913 | 0.79 | HRH1 (0.51) | KDM4EHRH1 | |
| Bromide SCHEMBL3553550 | 0.79 | POLB (0.59) | KDM4EPOLBHRH1TACR2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401838-B1 | NOVEL SUBSTITUTED TETRACYCLIC IMIDAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE AS A MEDICINE | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-26 | — | — | EP | disclosed |
| EP-1401838-B1 | NOVEL SUBSTITUTED TETRACYCLIC IMIDAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE AS A MEDICINE | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-26 | — | — | EP | disclosed |
| US-7732437-B2 | Use of anti-histaminics for acute reduction of elevated intracranial pressure | JANSSEN PHARMACEUTICA, NV. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-7732437-B2 | Use of anti-histaminics for acute reduction of elevated intracranial pressure | JANSSEN PHARMACEUTICA, NV. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-7732437-B2 | Use of anti-histaminics for acute reduction of elevated intracranial pressure | JANSSEN PHARMACEUTICA, NV. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-7476662-B2 | Substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-13 | — | — | US | disclosed |
| US-7476662-B2 | Substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-13 | — | — | US | disclosed |
| US-7476662-B2 | Substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-13 | — | — | US | disclosed |
| EP-1451196-B1 | The use of substituted tetracyclic imidazole derivatives as anti-histaminics | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| EP-1451196-B1 | The use of substituted tetracyclic imidazole derivatives as anti-histaminics | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050070525-A1 | Use of anti-histaminics for acute reduction of elevated intracranial pressure | JANSSEN-CILAG GMBH (DE) | 2005-03-31 | — | — | US | disclosed |
| EP-1451196-A1 | THE USE OF ANTI-HISTAMINICS FOR ACUTE REDUCTION OF ELEVATED INTRACRANIAL PRESSURE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-01 | — | — | EP | disclosed |
| US-20040167138-A1 | Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharamaceutical compositions comprising them and their use as a medicine | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-26 | — | — | US | disclosed |
| EP-1401838-A2 | NOVEL SUBSTITUTED TETRACYCLIC IMIDAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003044023-A1 | THE USE OF ANTI-HISTAMINICS FOR ACUTE REDUCTION OF ELEVATED INTRACRANIAL PRESSURE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-30 | — | — | WO | disclosed |
| WO-2002100862-A2 | NOVEL SUBSTITUTED TETRACYCLIC IMIDAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070525-A1 | Use of anti-histaminics for acute reduction of elevated intracranial pressure | HRH2, HRH3, HRH4 | KDM4E 3457/4885POLB 3028/4885HRH1 4/4885 |
| US-20040167138-A1 | Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharamaceutical compositions comprising them and their use as a medicine | AIFM1, PTGIS, ATP6V1B2 | KDM4E 4219/4885POLB 2179/4885HRH1 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.